Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy

Journal of Cystic Fibrosis

Volumn 16, Issue 2, 2017, Pages 246-249

  Marigowda, Gautham ^a   Liu, Fang ^a   Waltz, David ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; INDACATEROL; IPRATROPIUM BROMIDE; IVACAFTOR; LUMACAFTOR; SALBUTAMOL; TIOTROPIUM BROMIDE; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; BRONCHODILATING AGENT; CHLORIDE CHANNEL STIMULATING AGENT; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; COUGHING; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; SPIROMETRY; TREATMENT RESPONSE; VIRUS INFECTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; PROCEDURES; RESPIRATORY SYSTEM;

ADULT; AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; BRONCHODILATOR AGENTS; CHLORIDE CHANNEL AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HEALTHY VOLUNTEERS; HUMANS; MALE; QUINOLONES; RESPIRATORY SYSTEM; SPIROMETRY;

EID: 85007109976     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.11.001     Document Type: Article

References (5)

1. [1] Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
2. [2] Boyle, M.P., Bell, S.C., Konstan, M.W., McColley, S.A., Rowe, S.M., Rietschel, E., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
3. [3] Pawaskar, D., Marigowda, G., Waltz, D., Mahnke, L., Panorchan, P., The effect of ciprofloxacin, itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with ivacaftor in healthy individuals. Pediatr Pulmonol, 49(S38), 2014, 286.
4. [4] Cook, D.P., Rector, M.V., Bouzek, D.C., Michalski, A.S., Gansemer, N.D., Reznikov, L.R., et al. Cystic fibrosis transmembrane conductance regulator in sarcoplasmic reticulum of airway smooth muscle. Implications for airway contractility. Am J Respir Crit Care Med 193 (2016), 417–426.
5. [5] Ramsey, B.W., Davies, J., McElvaney, G., Tullis, E., Bell, S.C., Dřevínek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.